anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject agent composed of a compound obtained by the extraction of a plant body of a labiate, little in irritation to the skin, excellent in percutaneous absorbefacient activity and capable of stimulating percutaneous absorption of an active component when compounded in a composition for external use for skin. SOLUTION: This agent consists of a compound of the formula (R is formyl, a 1-4C acyloxymethyl, a 1-4C alkoxymethyl, hydroxymethyl, a hyroxymethyl to which a sugar residue binds through an ether bonding). Preferable examples of the compound of the formula include perilla alcohol and perillaldehyde. A compound of the formula is obtained, for example, from a plant body of a labiate by the fractional purification of a distillate or an extract obtained by steam distillation or solvent extraction. The compound can enhance the percutaneous absorption of an active component when compounded with the active component in a composition for an external preparation for skin. Further, the compounding ratio of the agent in the composition is preferably 0.01-20wt.%.
Inflammatory bowel disease (IBD), characterized primarily by gastrointestinal inflammation, predominantly manifests as Crohn's disease (CD) and ulcerative colitis (UC). It is acknowledged that Inflammation plays a significant role in cancer development and patients with IBD have an increased risk of various cancers. The progression from inflammation to carcinogenesis in IBD is a result of the interplay between immune cells, gut microbiota, and carcinogenic signaling pathways in epithelial cells. Long-term chronic inflammation can lead to the accumulation of mutations in epithelial cells and the abnormal activation of carcinogenic signaling pathways. Furthermore, Immune cells play a pivotal role in both the acute and chronic phases of IBD, contributing to the transformation from inflammation to tumorigenesis. And patients with IBD frequently exhibit dysbiosis of the intestinal microbiome. Disruption of the gut microbiota and subsequent immune dysregulation are central to the pathogenesis of both IBD and colitis associated colorectal cancer (CAC). The proactive management of inflammation combined with regular endoscopic and tumor screenings represents the most direct and effective strategy to prevent the IBD-associated cancer.
PURPOSE: Nigeria has the highest burden of breast cancer (BC) in Africa. While the survival rates for BC are over 90% in many high-income countries; low-and middle-income countries like Nigeria have 40% BC survival rates. Prior studies show that the burden and poor BC survival rates are exacerbated by both health system and individual level factors, yet there is a paucity of literature on the experiences of BC survivors in Nigeria. Hence, this study explored the divergent and convergent experiences of BC survivors in accessing, navigating, and coping with treatment.
METHODS: Participants (N = 24, aged 35 to 73 years) were recruited and engaged in focus group discussions (group 1, n = 11; group 2, n = 13 participants). Transcripts were transcribed verbatim and analyzed with inductive thematic analysis.
RESULTS: Four themes were identified: "I am carrying this [breast cancer] alone," "Living my life," "'God' helped me," and "A very painful journey." Participants described how they concealed their BC diagnosis from family and significant others while accessing and navigating BC treatment. Also, they adopted spiritual beliefs as a coping mechanism while sticking to their treatment and acknowledging the burden of BC on their well-being.
CONCLUSIONS: Our findings explored the emotional burden of BC diagnosis and treatment and the willingness of the BC survivors to find meaning in their diagnosis. Treatment for BC survivors should integrate supportive care and innovative BC access tools to reduce pain and mitigate the burdens of BC.
IMPLICATIONS FOR CANCER SURVIVORS: The integration of innovative technologies for venous access and other treatment needs of BC is crucial and will improve survivorship. Non-disclosure of BC diagnosis is personal and complicated; hence, BC survivors need to be supported at various levels of care and treatment to make meaningful decisions. To improve survivorship, patient engagement is crucial in shared decision-making, collaboration, and active participation in care.
This is a randomized (study medication assigned to participants by chance), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), open-label (participants and researchers are aware about the treatment, participants are receiving), multicenter (when more than 1 hospital or medical school team work on a medical research study), study in virologically-suppressed, HIV-1 infected adult participants. The study will include a Screening Period of approximately 30 days (up to maximum 6 weeks), a controlled Treatment Period of 48 weeks, an Extension Phase of 48 weeks. All eligible participants will be randomly assigned to receive either current treatment regimen - a bPI (limited to DRV with low-dose ritonavir \[rtv\] or COBI, atazanavir \[ATV\] with rtv or COBI, or lopinavir \[LPV\] with rtv) combined with FTC/TDF, or experimental treatment regimen - D/C/F/TAF once-daily single-tablet for 48 weeks. After completion of week 48, participants assigned to the experimental treatment will continue with D/C/F/TAF in the extension phase up to week 96 . Participants who continued their current regimen will receive the experimental treatment (if all criteria are fulfilled) at week 52 up to week 96. As from Week 96, all participants will be given the option to continue D/C/F/TAF treatment, if they wish and if they continue to benefit from it until D/C/F/TAF becomes commercially available and is reimbursed, or can be accessed through another source in the country where he/she is living,or until the sponsor terminates clinical development. A bone investigation substudy will be performed at selected study sites, to assess bone biomarkers and energy x-ray absorptiometry (DXA) scans, in approximately 300 participants (200 in the D/C/F/TAF treatment arm versus 100 in the control arm) who provide informed consent for the substudy.
PURPOSE:Hydrogel having improved adaptability to organism and fracture elongation, obtained by polymerizing a specific polyethylene glycol, etc. with a specified hydrophobic monomer, etc. in a specific ratio. CONSTITUTION:95-40pts.wt. polyethylene glycol or poly(ethylene glycol-propylene glycol) copolymer shown by the formula I (m is positive integer; n is 0 or positive integer; R1 is group shown by the formula II, III, IV, V, VI, or VII; R2 is H, or CH3), having polymerizable double bonds at both ends and 1,500-500,000 molecular weight is polymerized with 5-60pts.wt. hydrophobic monomer (e.g., styrene, etc.) having a polymerizable double bond and/or hydrophobic polymer having a polymerizable double bond in the molecule, to give the desired hydrogel. USE:Medical materials such as catheters, soft contact lenses, etc.
Cisplatin Injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neurologic symptoms have been reported to occur after a single dose. Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of Cisplatin Injection. Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. The neuropathy may progress further even after stopping treatment. Peripheral neuropathy may be irreversible in some patients.

Perform a neurological examination before initiating Cisplatin Injection, at appropriate intervals during therapy, and after completion of therapy. Consider discontinuation of Cisplatin Injection for patients who develop symptomatic peripheral neuropathy. Geriatric patients may be more susceptible to peripheral neuropathy [see Use in Specific Populations (8.5)].
Fentanyl transdermal matrix patch is a narcotic analgesic agent. Compared with the existing reservoir-type Durotep® Patch, fentanyl transdermal matrix patch is not liable to leakage of drug solution and does not contain alcohol, which becomes a cause of skin irritation. Also this new formulation has become available in a smaller dose of 12.5mg/hr while the smallest Durotep® Patch is 25mg/hr. While Durotep® Patch is currently indicated only for cancer pain in Japan, this clinical trial was planned to assess effectiveness, and safety of fentanyl transdermal matrix patch in Japanese patients with chronic intractable pain receiving codeine, morphine hydrochloride, or fentanyl injectable formulations. After pre-treatment period for seven to fourteen days for evaluating the eligibility of the patients for the study, patients will be treated for 4 weeks as Treatment period 1 and 48 weeks as Treatment period 2 followed by 3-day post-treatment observation period. One patch can be used for 72 hours, which is the same as the existing Patch. Starting from the first day of treatment, fentanyl will be applied to the chest, the upper arm or other appropriate site, which will be replaced with a new patch every three days (ca. 72 hr). Starting dose should be between 12.5 mcg/hr and 75 mcg/hr, depending on the prior opioid dose.
The invention belongs to the field of preparation of a functional nano-composite material and relates to a preparation method of a fluorescent nano-composite having drug-release function. The fluorescent nano-composite can be used for monitoring the release progress of a drug via changes of fluorescence intensity. A main body of the fluorescent nano-composite is a nano-composite which is of a core-shell structure formed by metal nanometer particles and biological macro-molecules; a biocompatible polymer (such as a polylysine molecule) and a medicinal adriamycin amycin molecule are cross-linked and polymerized on the surface of a metal nanometer particle to form a polymer shell layer for covering the adriamycin amycin molecule. When glutathione with a certain concentration exists in the environment, a disulfide bond in a crosslinking agent is cut off, and then adriamycin amycin is released from the polymer shell layer. Meanwhile, due to changes of the thickness of the shell layer, the release progress of the drug can be sensitively and effectively represented by detecting the changes of the fluorescence intensity of fluorescent molecules coating the surface of the nano-composite according to distance dependency of metal reinforced fluorescence effect. The functional nano-composite material disclosed by the invention has quite good application prospect in the field of sentinel release treatment of drugs.
The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine combination for treating constipation type of cough during pregnancy. The medicine combination is based on etiology and pathogenesis, a number of raw materials are carefully selected, including herb of flabellate hemipilia , pholidota chinensis, potentilla reptans L., disrum brachystemon Wang et Tang, all-grass of shore podgrass, Chinese ash flower, asplenium saxicola ros, sarcopyramis nepalensis wall. var. maculata C.Y. Wu ex C. Chen, pilea pumila, Japanese apricot branchlet and leaf. The traditional Chinese medicine combination has the effects of nourishing yin and moisturizing lung, helping producing salivia and slaking thirst, relieving cough and asthma, calming nerves, protecting fetus and preventing miscarriage, can effectively control the development of a disease condition, with no relapse after the recovery. It is proved by the clinical test that the total effective rate is 95.24%. The medicine combination deserves to be promoted in the clinical field.
The present invention discloses a norcantharidin film-coated tablet, which is characterized in that a norcantharidin plain tablet of which the diameter is 0.5cm to 0.8cm with an oblate shape is used as a tablet base. The surface of the plain tablet is sprayed and coated with one layer of coating material: a film-coated layer, and the thickness of the coating material is 0.3mm to 1.0mm, wherein the coating material is used as moisture-proof type opadry. The preparation method of the norcantharidin film-coated tablet comprises a plain tablet preparation process and a film coat coating process. The present invention has the advantages of a small blank tablet, less supplementary material, and low cost; at the same time, the film-coated tablet made up has good humidity resistance and strong stability; the dissolution velocity of the tablet is enhanced, and bioavailability and clinic curative effect are enhanced. The present invention is suitable for liver cancer, esophagus cancer, stomach and cardiac cancer, etc. and white blood cell deficiency symptom, hepatitis, hepatic cirrhosis, and a hepatitis B virus carrier; the present invention can be also used as premedicant or on combined chemotherapy; at the same time, operating limitation to a diabetic is relieved.
In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can result in clinical infections, including disseminated infections. The concurrent administration of live vaccines with RENFLEXIS is not recommended.

Fatal outcome due to disseminated BCG infection has been reported in an infant who received a BCG vaccine after in utero exposure to infliximab products. Infliximab products are known to cross the placenta and have been detected up to 6 months following birth. At least a six month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.

Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with RENFLEXIS.

It is recommended that all pediatric patients be brought up to date with all vaccinations prior to initiating RENFLEXIS therapy. The interval between vaccination and initiation of RENFLEXIS therapy should be in accordance with current vaccination guidelines.
Oxygen gas at 1 to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with increased inspired CO2 concentration produced by having the subject rebreathe some of their exhaled air. Total treatment is for 14 days.
552,751. Organic acid salts of silver and lead. WARD BLENKINSOP & CO., Ltd., YORKSHIRE DYEWARE & CHEMICAL CO., Ltd., CRAVEN, A. B., and PRITCHARD, G. F. Nov. 18, 1941, No. 14824. [Class 1 (iii)] [Also in Groups IV and VI] Silver or lead compounds having anti-bacterial effect and suitable for application to the skin, e.g. in the treatment of burns are obtained by reacting silver or lead compounds such as the oxides or hydrates with a di-substituted methane, referred to as a D.S.M. compound and having the formula R 1 R 2 CH 2  in which R, may be a phenol sulphonic acid, a diphenyl sulphonic acid, a benzene sulphonic acid, a sulpho benzoic acid, a naphthalene sulphonic acid, a naphthol sulphonic acid, a nuclear substituted halogen derivative of any of the above and R 2  may be any one of the same. The compounds may be used in solution or in the form of powders, emulsions, ointments &c. and also in conjunction with other medicinal substances, e.g. sulphanilamide, or acriflavine. The production of D.S.M. compounds in solution which is afterwards reacted with silver and lead compounds is described in the Specification. The reactions mentioned are the heating formaldehyde respectively with naphthalene-2-sulphonic acid, with naphthalene 2:7 disulphonic acid, and with 2-naphthol 6-sulphonic acid.
The invention discloses an externally applied patch for treating gynecological myoma of uterus and ovarian cyst. The externally applied patch consists of marmor serpentinatum, sulfur, clove, cinnamon, radix angelicae, Astragalus membranaceus, frankincense, myrrh, fennel, rheum officinale, Chinese blister beetles, Sargassum, selfheal, dragon's blood, crude sichuan aconite roots, radix aconite, white spirit, rice vinegar and active carbon iron powder. Most of the medicinal raw materials of the patch are yang-warming medicines. Medicines for promoting blood circulation to remove blood stasis can improve microcirculation, increase the blood flow volume, change the rheological property of blood and promote obsolete bleeding absorption in mesometrium without envelope. Medicines for softening hardness and transforming phlegm can promote macrophage proliferation and release of connective tissues, so that proliferous fiber cyst in the mesometrium is softened. Aiming at etiology and pathogenesis of the symptoms, the externally applied patch disclosed by the invention warms and invigorates kidney yang, disperses blood stasis, tonifies qi and yang and warms kidneys without the deficiency of improving too much yang to cause heat. As the patch directly reaches focuses and is quickly transdermal, so as to take effect quickly. The effective components of the medicines directly reach the focuses.
The present invention provides a distinguishing method for measuring the dissolution profile of megestrol acetate suspension. The method includes the following steps: dissolving a surfactant in water to prepare a dissolving medium, wherein the surfactant includes sodium lauryl sulfate or polysorbate 80. The mass concentration of sodium lauryl sulfate ranges is from 0.35% to 0.45% while the surfactant is sodium lauryl sulfate; the mass concentration of polysorbate 80 ranges is from 0.8% to 1.0% while the surfactant is polysorbate 80. Then, shake the megestrol acetate oral suspension well, and prepare the samples after decompression and degassing. The samples are added to the dissolving medium through the automatic sample adding device, and the measurement is carried out according to the dissolution device stirring paddle method. Finally, take samples at sampling time points to determine the amount of dissolution at different time points.
FIELD: medicine. SUBSTANCE: method includes reflex-correcting therapy course. This therapy is performed by mechanical compression and petrissage of radicular and reflex zones in tissues of back and sacrolumbar region. Then series of blows with palm is delivered in the direction from vertebral column center to periphery. Force effect is rendered on reflex-dependent skin receptors of actuation and control of pelvis organ function, and mechanical pressure is applied to points on head, in Broca's area. Complex of physical actions is combined with course of breathing and physical Yoga exercises, with complex of exercises in squatting and walking on the spot and with tapping on vertebral column. Use may also be made of hot water bag application to loin, as well as of hot baths up to the waist which must be continued for one month longer after time of treatment is over. In addition, infusion of medical herbs is taken. Species of medical herbs contains sweet clover, milfoil, wild marjoram, plantain, nettle, dandelion, lady's mantle, and dead nettle at the following relation of components by mass: 1:2:2:4:2: 2:2:2. EFFECT: enhanced therapeutic efficiency. 3 cl, 2 ex
Allogeneic blood transfusion is often done during surgery to save life- threatening conditions. Blood conservation is a method that can reduce peri-operative allogeneic blood transfusion. This study has been conducted on 34 patients underwent laparotomy surgery with bleeding more than 20% of EBV. After being informed concent, research subjects were randomized into two groups: ANH (conducted ANH) and control group (without ANH). After starting general anesthesia, the ANH group was withdrawing blood based on Gross formula. Restoration of circulated volume was instituted by infusion of colloids. In control group, the operation was started right after the induction of anesthesia. The monitoring of blood pressure, heart rate, the amount of bleeding, total fluid, urine production, hemoglobin concentration and number of allogenic transfusion were recorded.
Background: Intermittent fasting may be an effective tool for weight loss, but it is still unclear from previous studies to date whether it is as effective as a continuous energy restriction in terms of reducing adipose tissue and whether it leads to unwanted muscle loss. Objectives: The aim of this study was to compare the effect of intermittent fasting (IF) with continuous energy restriction (CER) on the body weight and body composition and to assess the effect of intermittent fasting also in isolation from the energy restriction. Methods: After completion of a three-week dietary intervention, differences in the weight loss and differences in the body composition were compared between three groups. The first group consumed 75% of their calculated energy intake requirements in a six-hour time window. The second group consumed 75% of their calculated energy intake requirements without a time window and the third group consumed 100% of their calculated energy intake requirements in a six-hour time window. The changes in the weight and body composition were assessed by BIA. Results: Of the 95 randomized participants, 75 completed the intervention phase of the study. The highest mean weight loss was achieved by the IF with ER (energy restriction) group (2.3 ± 1.4 kg), followed by the CER group (2.2 ± 1.1 kg); the difference between the groups did not reach statistical significance. The lowest mean weight loss was observed in the IF without ER group (1.1 ± 1.2 kg), the difference reaching statistical significance compared to the IF with ER (p=0.003) and CER (p=0.012) groups. The highest mean adipose tissue loss was observed in the CER group (1.5 ± 1.2 kg) followed by the IF with ER group (1.3 ± 1.1 kg), with no statistically significant differences between the groups. A mean adipose tissue loss was found in the IF without ER group (0.9 ± 1.1 kg) with no statistically significant differences compared to the IF with ER and CER groups. The highest mean fat-free mass loss was found in the IF with ER group (1.1 ± 1.0 kg), followed by the CER group (0.65 ± 0.91 kg) with no statistically significant differences. The IF without ER group showed the lowest mean fat-free mass loss (0.2 ± 1.3 kg), which reached statistical significance compared to the IF with ER group (p=0.027). Conclusion: The results showed a comparable effect in the weight loss and body fat reduction regardless of the timing of the food intake. The diet quality, together with the energy intake, appeared to be one of the most important factors influencing the body composition.
Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.